Barinthus Biotherapeutics plc - VACC STOCK NEWS

Vaccitech to host KOL Webinar discussing treatment landscape for chronic Hepatitis B and potential cure paths.

Vaccitech plc will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023. The trial showed meaningful reductions of HBsAg in participants who received VTP-300 alone or in combination with a low-dose PD-1 inhibitor. Two patients achieved a non-detectable HBsAg level that persisted for eight months after the last dose. VTP-300 led to a decline in HBsAg in adults with chronic Hepatitis B, and VTP-300-elicited T cells showed cross-reactivity to HBV core antigen from genotypes A to E in vitro.

Vaccitech plc (NASDAQ: VACC) announced the topline data from the APOLLO clinical trial of VTP-200, a treatment for women with low-grade cervical lesions due to human papillomavirus (HPV). The study, which is in Phase 1b/2, showed that VTP-200 was well-tolerated with no serious adverse events. Initial immunogenicity results reported significant T cell responses to E1, E2, and E6 antigens, with 26 of 29 participants responding positively. The trial aims to address the lack of treatment options for women with persistent HPV infections, a condition affecting approximately 291 million women globally. Vaccitech plans to present final results in 2024, focusing on the clearance of infection and cervical lesions.

Pharmaron Beijing Co. has announced a substantial expansion of its Gene Therapy CDMO facility in Liverpool, UK, after securing a grant from the UK Government’s Life Sciences Innovation Manufacturing Fund. This £151M project will quadruple its gene therapy development capacity, adding over 8,000 sqM focused on viral vector, DNA, and RNA production. The expansion, which began in January 2023 and is expected to complete in 2024, aims to support 29 ongoing gene therapy and vaccine projects and bolster Pharmaron's scientific team. The facility was acquired from AbbVie in 2021, and growth is anticipated to continue through the existing operations.

Vaccitech plc (NASDAQ: VACC) announced successful completion of its Phase 1b/2a trial for VTP-300, showing positive results in reducing Hepatitis B surface antigen (HBsAg). The trial involved 55 patients, demonstrating VTP-300's generally favorable tolerability with no Grade 3 adverse effects. Notably, patients with lower baseline HBsAg saw significant declines. The final data will be presented at the EASL Congress in June 2023. CEO Bill Enright expressed optimism about VTP-300's potential to serve as a functional cure for chronic HBV, aiming to eliminate chronic treatment needs. Future studies will explore additional dosing and combination therapies.

Vaccitech plc (NASDAQ: VACC) reported strong financial results for 2022, achieving revenue of $44.7 million compared to $0.3 million in 2021, primarily from milestone payments related to AstraZeneca's Vaxzevria® sales. The company focuses on advancing immunotherapies and reported a net income of $5.3 million, up from a loss of $50.9 million the previous year. Significant accomplishments included successful enrollment in clinical trials, a 121% increase in R&D staff, and the opening of state-of-the-art facilities in the US and UK. The outlook for 2023 is promising with multiple data readouts expected.

Vaccitech plc (NASDAQ: VACC) announced positive interim results from the HPV001 study, a Phase 1b/2 trial for its investigational product, VTP-200. The trial, targeting women with low-grade cervical HPV lesions, reported no serious adverse events and favorable immunogenicity results, particularly concerning E1, E2, and E6 antigens. The study will continue towards its primary endpoint at 12 months. The CEO emphasized the importance of VTP-200 as a potential treatment for HPV infections, which currently have no options until high-grade lesions develop. Data will be presented at the International Papillomavirus Conference in April 2023.